RAPPRapport Therapeutics, Inc.
Price
+16%1YEnd-of-day closes, not the intraday tick.
The five questions
2 of 5 availableOnly two of the five can be answered for RAPP today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Watch
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Mixed
We are a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders. Our foundational science has elucidated the complexities of neuronal receptor biology and enables us to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor associated proteins (“RAPs”), the latter of which play crucial roles in regulating receptor expression and function.
In the company’s own words · 10-K filed Mar 10, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Rapport Therapeutics, Inc. (RAPP) reported revenue of $0 in Q2 2026 (quarter ended Jun 30, 2026). That came with net loss of $57M. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 5, 2026Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update.Earnings release · press release
- May 7, 2026Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update.Earnings release · press release
- Apr 21, 2026On April 21, 2026, the Company announced results from the 8-week follow-up period of its Phase 2a trial of RAP-219 in focal onset seizures (“FOS”)Regulation FD disclosure · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Biotechnology
The closest names by size in the same industry